title: Goserelin cannot improve the weakness of a patient with kennedy disease after 40-week administration.
authors.affiliation: Department of Neurology, Shanghai Changhai Hospital, Shanghai, China.
authors.forename: Zhi-Guang
authors.initials: ZG
authors.lastname: Shi
authors.forename: De-Ke
authors.initials: DK
authors.lastname: Jiang
authors.forename: Mei
authors.initials: M
authors.lastname: Zhao
authors.forename: She-Qing
authors.initials: SQ
authors.lastname: Zhang
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D055534:Bulbo-Spinal Atrophy, X-Linked / Q000150:complications* / Q000235:genetics; D005221:Fatigue / Q000188:drug therapy / Q000209:etiology; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D018908:Muscle Weakness / Q000188:drug therapy* / Q000209:etiology*; D011944:Receptors, Androgen / Q000235:genetics; D017211:Treatment Failure; D019680:Trinucleotide Repeat Expansion / Q000235:genetics
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011944:Receptors, Androgen; D017273:Goserelin